Stocks gained Wednesday despite minutes from the lastest FOMC meeting which showed the Fed is laser-focused on getting inflation under control. Amid the upside, several rumors...
Benzinga - The Office of Texas Representative Nicholas V. Taylor has reported a sale of Bristol-Myers Squibb (NYSE:BMY) stock on December 26, 2022. According to the Periodic...
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by...
Despite stock market declines, 65 new ETFs were listed in Q2 Fidelity has over $30 billion in assets under management 3 ETFs for investors looking to diversify portfolios There...
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
|Average||82.11 (+13.99% Upside)|
|No. of Analysts||18|